Category Archives: Industry
“The CE mark allows LumiThera to begin commercialization throughout the 28 EU member states and coincides with the initiation of the LIGHTSITE II Clinical Study in select European sites in the upcoming months,” stated Clark Tedford, Ph.D., LumiThera President and CEO. “We are excited to be able to offer a safe and effective early stage clinical intervention for patients with dry AMD.”
“It is very exciting to see the development of PBM treatment for dry AMD patients,” stated Samuel Markowitz, M.D., Department of Ophthalmology and Vision Sciences, University of Toronto. “These patients have limited options and losing their central vision is horribly debilitating to their quality of … Continue reading
Low-level laser therapy for preventing or treating oral mucositis caused by radiotherapy or chemotherapy
RESULT: After three presentations and much correspondence over a 5 year period we have a recommendation guideline from the National Institute of Health and Care Excellence (NICE) — LLLT for preventing or treating oral mucositis caused by radiotherapy or chemotherapy. This means the NHS can start using our treatment on cancer patients to reduce some of the painful side effects of cancer treatments.
Read here: https://www.nice.org.uk/guidance/ipg615
The LIGHTSITE I data was presented at the 2018 Association for Research in Vision and Ophthalmology (ARVO) annual conference by Marion Munk, MD, PhD, Department of Ophthalmology/Bern Photographic Reading Center and Managing Director, Bern Photographic Reading Center, University Hospital Bern. Dr. Munk was part of the investigator team.
“LumiThera PBM treatment demonstrated reductions in central drusen volume over the course of the one-year study versus the sham treatment with statistical significance at one year, (p = 0.05). Drusen is the hallmark pathology of dry AMD and is an important proinflammatory mediator and marker for disease progression,” says Dr. … Continue reading
Shepherd University has introduced Photobiomodulation to their advanced practice nurses and faculty members
Shepherd University in partnership with the Photobiomodulation Therapy Foundation, announced its new health education initiative Wednesday during a day-long workshop, which introduced PBM, or photobiomodulation, to Shepherd’s advanced practice nurses and faculty members. It is considered the first step in bringing the application of light-based treatments into the nursing curriculum.
“PBM is important to West Virginians,” said Dr. Sharon Mailey, acting dean for and chair of the … Continue reading
Shepherd University announces new strategic health education initiative.
Shepherd University and the PBM Foundation will tackle healing in a different way, by bringing the science and application of light-based treatments into their curriculum.
Read the full article and watch the video on localdvm.com
LumiThera® Inc., a clinical stage medical device company focused on delivering non-invasive photobiomodulation (PBM) therapies for ocular disorders and disease, today announced it has been awarded the prestigious “MOST INNOVATIVE AND PROMISING MEDTECH & E-HEALTH COMPANY” during Biovision 2017 in Lyon, France.
This is great news for patients suffering from dry AMD who have no other treatment alternatives!
Read the full press release:
LumiThera Named Most Innovative And Promising Medtech & E-Health Company At Biovision 2017
Disclosure: I am an investor in Lumithera a) because it successfully treats an unmet medical need, (dry AMD) b) I … Continue reading
The good news is I received an invite from NICE to go see them.
NICE are the UK’s National Institute for Health and Clinical Excellence. Their guidance helps British health professionals deliver the optimal care based on the best available evidence. It seems they like what we do and want me go show them LLLT. Watch this space. 8-)